Identification of the involvement of potassium channels in fibromyalgia
K Lawson - Frontiers in Bioscience-Scholar, 2022 - shura.shu.ac.uk
Fibromyalgia is a central sensitivity syndrome that presents with chronic pain, fatigue,
cognitive dysfunction, and disordered sleep. The pathophysiology which due to multisensory …
cognitive dysfunction, and disordered sleep. The pathophysiology which due to multisensory …
KCNH2-3.1 mediates aberrant complement activation and impaired hippocampal-medial prefrontal circuitry associated with working memory deficits
Increased expression of the 3.1 isoform of the KCNH2 potassium channel has been
associated with cognitive dysfunction and with schizophrenia, yet little is known about the …
associated with cognitive dysfunction and with schizophrenia, yet little is known about the …
Inhibition of cloned hERG potassium channels by risperidone and paliperidone
HJ Lee, JS Choi, BH Choi, SJ Hahn - Naunyn-Schmiedeberg's archives of …, 2017 - Springer
Risperidone and one of its active metabolites, paliperidone, are widely used for the
treatment of schizophrenia. We used a patch-clamp study to investigate the effects of …
treatment of schizophrenia. We used a patch-clamp study to investigate the effects of …
Analysis of CACNA1C and KCNH2 Risk Variants on Cardiac Autonomic Function in Patients with Schizophrenia
A Refisch, S Komatsuzaki, M Ungelenk, A Schumann… - Genes, 2022 - mdpi.com
Background: Cardiac autonomic dysfunction (CADF) is a major contributor to increased
cardiac mortality in schizophrenia patients. The aberrant function of voltage-gated ion …
cardiac mortality in schizophrenia patients. The aberrant function of voltage-gated ion …
[PDF][PDF] ESTABLISHMENT AND UTILIZATION OF A DRUG DISCOVERY PLATFORM FOR KV11. 1-3.1, A NOVEL TARGET FOR THE TREATMENT OF …
NE Calcaterra - 2016 - jscholarship.library.jhu.edu
The recently discovered primate brain-specific voltage-gated potassium channel, Kv11. 1-
3.1, was previously identified as a possible therapeutic target for the treatment of …
3.1, was previously identified as a possible therapeutic target for the treatment of …